March 10th 2025
Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal disease
Eye Care Symposia in Los Angeles
April 25-26, 2025
Register Now!
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (CME Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (CME Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (COPE Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (COPE Track)
View More
Surv.AI Says: Real-World Insights Into Patient Burden & Evolving Strategies in nAMD and DME (CME Credit)
View More
Surv.AI Says: Real-World Insights into Patient Burden & Evolving Strategies in nAMD and DME (COPE Credit)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (COPE Track)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (COPE Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (CME Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (COPE Track)
View More
19th Annual Controversies in Modern Eye Care
May 4, 2025
Register Now!
(CME Track) Community Practice Connections™: Advancing the Optimal Diagnosis & Treatment of Thyroid Eye Disease
View More
(COPE Track) Community Practice Connections™: Advancing the Optimal Diagnosis & Treatment of Thyroid Eye Disease
View More
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Collaborative Care Symposium
May 30-31, 2025
Register Now!
Outlining the New Standard in Geographic Atrophy: Optimizing Care Within the Modern Treatment Paradigm (CME Track)
View More
Outlining the New Standard in Geographic Atrophy: Optimizing Care Within the Modern Treatment Paradigm (COPE Track)
View More
Community Practice Connections™: Novel Therapies for Neovascular Retinal Disease – Expert Analysis of New Key Data
View More
Practical Approaches to Modern Dry Eye Treatment and Management
June 25, 2025
Register Now!
Latest Advances in X-Linked Retinitis Pigmentosa: Optimizing Diagnosis and Developments in Gene Therapy
View More
Cases & Conversations™: Real World Review of Treat and Extend Strategies for Neovascular Retinal Disease
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (CME Track)
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (COPE Track)
View More
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (COPE Track)
View More
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (CME Track)
View More
Community Practice Connections™: Navigating Complexities in Neurotrophic Keratitis — A Roadmap for Advanced Patient Care (CME Credit)
View More
Community Practice Connections™: Navigating Complexities in Neurotrophic Keratitis — A Roadmap for Advanced Patient Care (COPE Credit)
View More
Optic disc abnormality predictive of future visual-field loss
August 1st 2003Fort Lauderdale, FL-Both Heidelberg Retina Tomograph (HRT, Heidelberg Engineering) exams and stereoscopic optic disc photographs can show abnormalities that pre- dict glaucomatous visual-field abnormalities as early as 4 years before visual-field conversion occurs, according to results of an analysis conducted at the University of California San Diego, La Jolla.
Read More
Detection of glaucoma progression critical
August 1st 2003Fort Lauderdale, FL-What constitutes glaucoma progression and the relationship between progressive structural and functional injury? These were the main questions researchers set out to answer during a glaucoma mini-symposium at the annual meeting of the Association for Research in Vision and Ophthalmology.
Read More
Retinal thickness analyzer gives more precise information
June 1st 2003Dayton, OH-Move over a few disc diameters from the optic nerve head to assess the retinal thickness in the para-macular region for early diagnosis and close monitoring of the glaucomatous process. That's the message of Talia Technology Inc., Tampa.
Read More
Transition begins after Pfizer-Pharmacia merger
June 1st 2003New York-Pfizer Inc. will invest $400 million to expand its New Jersey facilities and potentially add 1,300 jobs, but plans to close five research and development sites around the world-including two in the United States- and other former Pharmacia Corp. offices as it begins the difficult logistical transition of its $57 billion takeover.
Read More
HLA-B27-associated anterior uveitis a common presentation
June 1st 2003Editor's Note: Anterior uveitis is the most common type of intraocular inflammation. Among patients with inflammation localized primarily to the anterior chamber, 50% or more are HLA-B27 positive. Inaddition, a number of these patients with HLA-B27-associated anterior uveitis have, or will develop, an associated systemicdisorder such as ankylosing spondylitis,reactive arthritis (formerly known asReiter's syndrome), inflammatory bowel disease, or psoriatic arthritis.
Read More
CA-The FDA approval of gatifloxacin ophthalmic solution 0.3% (Zymar, Allergan) marks a milestone as the first fourth-generation fluoroquinolone to enter the ophthalmic market. The therapy for the treatment of bacterial conjunctivitis caused by susceptible strains of bacteria also has a unique mechanism to prevent development of antibiotic resistance, according to Allergan.
Read More
IOL edge design directly affects ability to see at night
April 15th 2003Salt Lake City-Dysphotopsias, the unwant-ed optical images seen at night, pose an annoying and sometimes debilitating effect for cataract patients receiving IOLs with a truncated edge. To minimize these effects, efforts to modify the IOL edge have paid off, according to Randall J. Olson, MD.
Read More
OHTS identifies thinner corneas as risk for visual changes
April 1st 2003Omaha, NE-The Ocular Hypertension Treatment Study (OHTS) clearly demonstrat-ed that topical IOP-lowering medications can delay the onset of primary open-angle glaucoma. In addition, the OHTS study also revealed two very important secondary messages, which may be as important as the primary finding, according to M. Roy Wilson, MD.
Read More
Brimonidine may replace beta-blockers for older patients
November 15th 2002Tucson, AZ-Topical beta-blockers have been a mainstay of ongoing treatment for glaucoma for more than 20 years, but a new study adds to the evidence that they may not be the best option for long-term control of IOP for elderly patients.
Read More
Experts discuss implications of race on disease
November 15th 2002Editor's note: This is the second story in a three-part series covering a forum on "Ethnicity and Glaucoma" at Johns Hopkins University to commemorate the 20th anniversary of the Baltimore Eye Study. The meeting was sponsored by Johns Hopkins University School of Medicine and Ophthalmology Times and supported through an unrestricted educational grant from Alcon Laboratories Inc.
Read More
Clinicians take heed with new glaucoma procedures
November 15th 2002Los Angeles-Considering the limited availability of published randomized trials, glaucoma surgeons should remain skeptical about the safety and efficacy of viscocanalostomy and deep sclerectomy with collagen wick, said Donald S. Minckler, MD.
Read More
Estrogen exposure may protect women against cataract
September 15th 2002Fort Lauderdale, FL-Estrogen-whether endogenous or from hormone replacement therapy (HRT)-appears to help prevent cataract formation, according to Australian researcher Christine Younan, MD, who reported her findings at the annual meeting of the Association for Research in Vision and Ophthalmology.
Read More
Many still focus on controlling IOP, despite new definition
July 15th 2002New York-The official definition of glaucoma has changed over the years to downplay the role of IOP, although IOP does remain a central issue in the treatment and prevention of the condition. Such was the conclusion drawn from discussions at the Glaucoma 2002 meeting here.
Read More
NSAIDs may interfere with glaucoma medication
July 1st 2002San Antonio, TX-Before prescribing one of the newer medications for glaucoma, clinicians should ask what drugs the patient may be taking for aches and pains-especially non-steroidal anti-inflammatory agents (NSAIDs), including something as innocuous as aspirin, said William E. Sponsel, MD.
Read More
Various options available for correcting induced hyperopia
June 15th 2002Boston-The incidence of overcorrection following PRK and LASIK is fortunately very small, generally less than 5%. Unfortunately, the incidence of consecutive hyperopia after RK is significantly greater and, over time, becomes higher with a hyperopic shift, said Helen K. Wu, MD.
Read More
Molecule engineered to target neovascularization in AMD
June 1st 2002A genetically engineered molecule designed to kill cancers by destroying their rapidly growing blood vessels offers a new line of attack against age-related macular degeneration (AMD) and other retinal conditions, said Alan Garen, PhD.
Read More
Smooth, accurate LASIK ablation possible for myopia
May 15th 2002New Orleans-A system incorporating a narrow-beam excimer laser with an active tracking system to detect minuscule eye motions is effective in the LASIK correction of myopia and astigmatism, according to Marguerite B. McDonald, MD, clinical professor of ophthalmology at Tulane University School of Medicine here.
Read More